| Name | Title | Contact Details |
|---|
Xperience Restaurant Group (XRG) is a leading operator of casual and fine dining restaurants specializing in Mexican cuisine. Founded in 1954 with its flagship brand, El Torito, the company has grown to operate approximately 56 to 68 restaurants across the United States, serving over 10 million guests annually and employing a dedicated team of more than 3,400 to 4,300 members. XRGs portfolio features well-known brands such as El Torito, Chevys Fresh Mex, and SOL Mexican Cocina, each offering unique dining experiences that highlight authentic Mexican flavors. The company is recognized for its innovative concepts, including Taco Tuesday and tableside presentations, which have significantly influenced the Mexican dining scene in the U.S. XRG is committed to delivering high-quality cuisine in a welcoming environment, focusing on both traditional flavors and culinary innovation to enhance guest experiences.
Sycamore is a specialty wholesale broker, focusing on hospitality, cannabis, energy and niche personal lines dwellings. Sycamore Specialty Underwriters started its wholesale broker operations in 2014. Partnering with insurance companies around the country, Sycamores goal is to make sure agents seeking specialized products have a one stop-shop to finding coverage for their clients.
We offer surplus lines products to California agents, primarily homeowners (HO3) and landlord (DF3) policies. Please visit our website for information on how to become appointed.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.